{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:49:04Z","timestamp":1783784944753,"version":"3.55.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T00:00:00Z","timestamp":1622419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Childhood cancer survivors (CCSs) who have undergone bone marrow transplantation with systemic chemotherapy and whole-body irradiation often experience impaired glucose tolerance with marked insulin resistance. Incomplete acquired diabetic lipodystrophy should be considered as a late complication of bone marrow transplantation. A 24-year-old Japanese female patient with incomplete acquired lipodystrophy, a CCS of acute lymphocytic leukemia at the age of 3 years, was treated for diabetes mellitus and dyslipidemia at our hospital. Administration of multiple daily insulin injections (70 units\/day), and oral administration of 500 mg\/day metformin, 15 mg\/day pioglitazone, and 200 mg\/day bezafibrate had proven ineffective for her metabolic disorders. Subcutaneous administration of metreleptin improved her insulin resistance and hypertriglyceridemia within a month; however, it failed to maintain adequate plasma glucose levels in the long term. When oral administration of 10 mg\/day empagliflozin was added to the metreleptin supplementation, her HbA1c value (National Glycohemoglobin Standardization Program) improved from 11% to 8%, which was maintained for an additional 18 months. This is the first case report of incomplete lipodystrophy that shows efficacy of a combination therapy with metreleptin and a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of diabetes and dyslipidemia. An SGLT2 inhibitor attenuates hyperglycemia through urinary glucose excretion and has been suggested to enhance lipid catabolism in the extra-adipose tissues, especially in the liver and skeletal muscles. Furthermore, metreleptin supplementation could enhance the action of the SGLT2 inhibitor by promoting satiety and lipolysis through the central nervous system. Combination therapy with metreleptin and an SGLT2 inhibitor was suggested to recover the volume of adipose tissue, possibly through improvement of insulin resistance in the adipose tissue. This report highlights the pathophysiological mechanism of an SGLT2 inhibitor in the improvement of glucose metabolism in non-healthy lean CCSs with insulin resistance. Administration of SGLT2 inhibitor, along with metreleptin supplementation, could be a good alternative therapy for diabetic lipodystrophy observed in CCSs. <\/jats:p>","DOI":"10.3389\/fendo.2021.690996","type":"journal-article","created":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T08:38:14Z","timestamp":1622450294000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy"],"prefix":"10.3389","volume":"12","author":[{"given":"Ayako","family":"Nagayama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanoko","family":"Moritaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Sonezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoichiro","family":"Kitajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Yoshinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Hasuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4351","article-title":"Long Term Cause Specific Mortality Among 34 489 Five Year Survivors of Childhood Cancer in Great Britain: Population Based Cohort Study","volume":"354","author":"Fidler","year":"2016","journal-title":"BMJ"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510795","article-title":"Reduction in Late Mortality Among 5-Year Survivors of Childhood Cancer","volume":"374","author":"Armstrong","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02717-3","article-title":"Impaired Glucose Tolerance and Dyslipidaemia as Late Effects After Bone-Marrow Transplantation in Childhood","volume":"356","author":"Taskinen","year":"2000","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40618-018-0887-z","article-title":"Diagnosis and Treatment of Lipodystrophy: A Step-by-Step Approach","volume":"42","author":"Ara\u00fajo-Vilar","year":"2019","journal-title":"J Endocrinol Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/js.2019-00251","article-title":"Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report","volume":"3","author":"Nagayama","year":"2019","journal-title":"J Endocr Soc"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1515\/jpem-2018-0356","article-title":"Acquired Partial Lipodystrophy With Metabolic Disease in Children Following Hematopoietic Stem Cell Transplantation: A Report of Two Cases and a Review of the Literature","volume":"32","author":"Hosokawa","year":"2019","journal-title":"J Pediatr Endocrinol Metab"},{"key":"B7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1507\/endocrj.EJ20-0325","article-title":"Metreleptin Worked in a Diabetic Woman With a History of Hematopoietic Stem Cell Transplantation (HSCT) During Infancy: Further Support for the Concept of \u2018HSCT-Associated Lipodystrophy\u2019","volume":"68","author":"Adachi","year":"2021","journal-title":"Endocr J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1172\/JCI129190","article-title":"What Lipodystrophies Teach Us About the Metabolic Syndrome","volume":"129","author":"Mann","year":"2019","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7326\/L16-0372","article-title":"Sodium-Glucose Cotransporter 2 Inhibitor Improves Complications of Lipodystrophy: A Case Report","volume":"166","author":"Kawana","year":"2017","journal-title":"Ann Intern Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1530\/EC-20-0082","article-title":"Improvement of Skeletal Muscle Insulin Sensitivity by 1-Week SGLT2 Inhibitor Use","volume":"9","author":"Goto","year":"2020","journal-title":"Endocr Connect"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting Renal Glucose Reabsorption to Treat Hyperglycaemia: The Pleiotropic Effects of SGLT2 Inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cld.424","article-title":"Emerging Quantitative MRI Biomarkers of Diffuse Liver Disease","volume":"4","author":"Bannas","year":"2015","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/nu10081080","article-title":"Dietary Approaches for Japanese Patients With Diabetes: A Systematic Review","volume":"10","author":"Yamada","year":"2018","journal-title":"Nutrients"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2012.59","article-title":"Weight Loss Induced by Chronic Dapagliflozin Treatment is Attenuated by Compensatory Hyperphagia in Diet-Induced Obese (DIO) Rats","volume":"20","author":"Devenny","year":"2012","journal-title":"Obes (Silver Spring)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon Stimulates Gluconeogenesis by INSP3R1-mediated Hepatic Lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.04.011","article-title":"Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis Through Adipose Tissue Crosstalk","volume":"23","author":"Stern","year":"2016","journal-title":"Cell Metab"},{"key":"B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cell.2015.08.055","article-title":"Sympathetic Neuro-Adipose Connections Mediate Leptin-Driven Lipolysis","volume":"163","author":"Zeng","year":"2015","journal-title":"Cell"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00045.2016","article-title":"Role of Leptin in Energy Expenditure: The Hypothalamic Perspective","volume":"312","author":"Pandit","year":"2017","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.12494","article-title":"Beneficial Effects of Sodium-Glucose Cotransporter 2 Inhibitors for Preservation of Pancreatic \u03b2-Cell Function and Reduction of Insulin Resistance","volume":"9","author":"Kaneto","year":"2017","journal-title":"J Diabetes"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-1","article-title":"Relationship Between Fluctuations in Glucose Levels Measured by Continuous Glucose Monitoring and Vascular Endothelial Dysfunction in Type 2 Diabetes Mellitus","volume":"12","author":"Torimoto","year":"2013","journal-title":"Cardiovasc Diabetol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2955","article-title":"Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4093\/dmj.2019.0208","article-title":"Use of SGLT-2 Inhibitors in Patients With Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations","volume":"44","author":"Sheu","year":"2020","journal-title":"Diabetes Metab J"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.690996\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T08:38:16Z","timestamp":1622450296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.690996\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,31]]},"references-count":24,"alternative-id":["10.3389\/fendo.2021.690996"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.690996","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,31]]},"article-number":"690996"}}